Aurinia reports second-quarter profit growth: what it means for Aurinia Pharmaceuticals stock

Published on 10/07/2026 at 00:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Net income rose 74 percent to USD 37.40 million on August 6, 2026. Aurinia Pharmaceuticals stock has a USD 17.67 target from six analysts.

AUR, CA05156V1022, Illustration mit AI erstellt.

Aurinia reported second-quarter 2026 profit growth, with net income rising 74 percent to USD 37.40 million for the three months ended June 30. Yahoo Finance reported the figures on September 16, 2026, citing results released on August 6, 2026.

Second-quarter profit widens

Total revenue reached USD 83.20 million in the second quarter, up 19 percent from the prior-year period, while LUPKYNIS net product sales climbed 19 percent to USD 79.40 million. The profit increase therefore outpaced revenue growth by 55 percentage points, giving investors a clear measure of operating leverage.

Operating cash flow reached USD 52.50 million in the quarter and USD 85.10 million in the first half of 2026. StockTitan reported that Aurinia repurchased 5.0 million shares for USD 74.90 million during the first half.

Guidance stays unchanged

Aurinia reiterated 2026 total revenue guidance of USD 315 million to USD 325 million and LUPKYNIS net product sales guidance of USD 305 million to USD 315 million. The unchanged outlook matters because the second-quarter revenue result and the full-year range describe different points in the same growth plan, rather than a new forecast.

The company is focused on autoimmune diseases and markets LUPKYNIS, an oral therapy for adults with active lupus nephritis. Its investor-relations page also identifies aritinercept as a development program, keeping the pipeline relevant alongside the commercial product.

The numbers mean cash funds expansion

The earnings profile is increasingly shaped by LUPKYNIS, which generated USD 79.40 million of quarterly product sales. That concentration supports cash generation, but it also leaves the investment case tied to one commercial product while Aurinia advances additional autoimmune programs.

For market context, MarketBeat reported on September 28, 2026, that six analysts had a Moderate Buy consensus and an average 12-month target of USD 17.67. The same report said quarterly earnings per share of USD 0.28 exceeded the USD 0.24 consensus, while revenue of USD 58.57 million fell short of the USD 80.45 million forecast.

Prior close remains dated

Aurinia Pharmaceuticals had a prior close of EUR 13.93 at Lang & Schwarz on October 5, 2026. The quote carries no usable same-day change for October 7, 2026, so the dated prior close is the relevant euro reference.

The further course of trading is shown by the continuously updated real-time quote of Aurinia Pharmaceuticals stock.